THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES

    公开(公告)号:US20240175086A1

    公开(公告)日:2024-05-30

    申请号:US18521390

    申请日:2023-11-28

    CPC classification number: C12Q1/6883 A61K31/522 A61K45/06 A61K2039/505

    Abstract: The present invention features, inter alia, methods of treating patients having a mast cell-mediated inflammatory disease, methods of determining whether patients having a mast cell-mediated inflammatory disease are likely to respond to a therapy (e.g., a therapy comprising an agent selected from the group consisting of a tryptase antagonist, an Fc epsilon receptor (FcεR) antagonist, an IgE+ B cell depleting antibody, a mast cell or basophil depleting antibody, a protease activated receptor 2 (PAR2) antagonist, an IgE antagonist, and a combination thereof), methods of selecting a therapy for a patient having a mast cell-mediated inflammatory disease, methods for assessing a response of a patient having mast cell-mediated inflammatory disease, and methods for monitoring the response of a patient having a mast cell-mediated inflammatory disease.

    QUANTIFICATION OF RNA MUTATION EXPRESSION
    66.
    发明公开

    公开(公告)号:US20240136013A1

    公开(公告)日:2024-04-25

    申请号:US18541590

    申请日:2023-12-15

    CPC classification number: G16B20/20

    Abstract: A method for quantifying ribonucleic acid (RNA) mutation expression. For each read pair of a read pair group, a set of contiguously aligned regions and a splice junction configuration are identified. Each read pair is within a selected range of a location of interest. Each read pair of the read pair group is classified based on the set of contiguously aligned regions and the splice junction configuration that correspond to each read pair, a reference genome, and a selected mutation. A mutation-centric output is generated for the read pair group.

Patent Agency Ranking